Last reviewed · How we verify

Furacin — Competitive Intelligence Brief

Furacin (NITROFURAZONE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nitrofurazone. Area: Infectious Disease.

marketed nitrofurazone Sterile alpha and TIR motif-containing protein 1 Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Furacin (NITROFURAZONE) — Takeda.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Furacin TARGET NITROFURAZONE Takeda marketed nitrofurazone Sterile alpha and TIR motif-containing protein 1 1945-01-01
Aciphex Aciphex University of Utah marketed Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3
Dexilant Dexilant Genuine Research Center, Egypt marketed Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (nitrofurazone class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Furacin — Competitive Intelligence Brief. https://druglandscape.com/ci/nitrofurazone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: